Climb Bio Stock Buy Hold or Sell Recommendation
| CLYM Stock | 2.10 0.17 7.49% |
Given the investment horizon of 90 days and your below-average risk tolerance, our recommendation regarding Climb Bio is 'Strong Sell'. The recommendation algorithm takes into account all of Climb Bio's available fundamental, technical, and predictive indicators you will find on this site.
Check out Climb Bio Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Climb Stock, please use our How to Invest in Climb Bio guide. Note, we conduct extensive research on individual companies such as Climb and provide practical buy, sell, or hold advice based on investors' constraints. Climb Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
Climb |
Execute Climb Bio Buy or Sell Advice
The Climb recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Climb Bio. Macroaxis does not own or have any residual interests in Climb Bio or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Climb Bio's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Climb Bio Trading Alerts and Improvement Suggestions
| Climb Bio generated a negative expected return over the last 90 days | |
| Climb Bio has high historical volatility and very poor performance | |
| Climb Bio has a very high chance of going through financial distress in the upcoming years | |
| Climb Bio was previously known as Eliem Therapeutics and was traded on NASDAQ Exchange under the symbol ELYM. | |
| Net Loss for the year was (35.12 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Latest headline from seekingalpha.com: Climb Bio set to join Nasdaq Biotech Index |
Climb Bio Returns Distribution Density
The distribution of Climb Bio's historical returns is an attempt to chart the uncertainty of Climb Bio's future price movements. The chart of the probability distribution of Climb Bio daily returns describes the distribution of returns around its average expected value. We use Climb Bio price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Climb Bio returns is essential to provide solid investment advice for Climb Bio.
| Mean Return | -1.33 | Value At Risk | -9.03 | Potential Upside | 6.21 | Standard Deviation | 4.81 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Climb Bio historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Climb Bio Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Climb Bio or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Climb Bio's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Climb stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -1.35 | |
β | Beta against Dow Jones | 0.33 | |
σ | Overall volatility | 4.80 | |
Ir | Information ratio | -0.28 |
Climb Bio Volatility Alert
Climb Bio exhibits very low volatility with skewness of 0.32 and kurtosis of 1.05. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Climb Bio's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Climb Bio's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Climb Bio Fundamentals Vs Peers
Comparing Climb Bio's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Climb Bio's direct or indirect competition across all of the common fundamentals between Climb Bio and the related equities. This way, we can detect undervalued stocks with similar characteristics as Climb Bio or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Climb Bio's fundamental indicators could also be used in its relative valuation, which is a method of valuing Climb Bio by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Climb Bio to competition |
| Fundamentals | Climb Bio | Peer Average |
| Net Income | (35.12 M) | 570.98 M |
| Total Debt | 2.87 M | 5.32 B |
| Number Of Employees | 9 | 18.84 K |
| Total Asset | 110.47 M | 29.47 B |
| Retained Earnings | (155.98 M) | 9.33 B |
| Working Capital | 107.42 M | 1.48 B |
| Net Asset | 110.47 M |
Note: Acquisition by Emily Pimblett of 5000 shares of Climb Bio subject to Rule 16b-3 [view details]
Climb Bio Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Climb . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Climb Bio Buy or Sell Advice
When is the right time to buy or sell Climb Bio? Buying financial instruments such as Climb Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Climb Bio in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Utilities Thematic Idea Now
Utilities
Highly leveraged corporations that deliver utilities such as power, water or gas to public or business. The Utilities theme has 30 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Utilities Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Climb Bio Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Climb Stock, please use our How to Invest in Climb Bio guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Climb Bio. If investors know Climb will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Climb Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Climb Bio is measured differently than its book value, which is the value of Climb that is recorded on the company's balance sheet. Investors also form their own opinion of Climb Bio's value that differs from its market value or its book value, called intrinsic value, which is Climb Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Climb Bio's market value can be influenced by many factors that don't directly affect Climb Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Climb Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Climb Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Climb Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.